Click here to view online. Add this email to your safelist.
Lokelma approved in China for the treatment of adult patients with hyperkalaemia
6 January 2020
AstraZeneca’s Lokelma (sodium zirconium cyclosilicate) has been approved in China for the treatment of adult patients with hyperkalaemia (elevated levels of potassium in the blood).
|
|||||
|
|||||
|
For more information please visit astrazeneca.com. If you would like to unsubscribe please click here. |
